icon-    folder.gif   Conference Reports for NATAP  
 
  26th Conference of the Asian Pacific
Association for the Study of the Liver
2017 APASL, Feb 15-19
Shanghai, China

Back grey_arrow_rt.gif
 
 
 
Safety, Efficacy, and Clinical Outcomes in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in the TOPAZ-I and TOPAZ-II Trials
 
 
  Reported by Jules Levin
26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), 15-19 February 2017, Shanghai, China
 
J George1, D Dieterich2, M Weltman3, R Skoien4, P Desmond5, J Sasadeusz6, KA Stuart7, P Dorr8, E Dumas8, M Charafeddine8, L Liu8, D Cohen8, P Martin9, HS Te10, M Sulkowski 11, D Shaw12, F Poordad13
 
1Westmead Hospital, Westmead, New South Wales, Australia; 2Icahn School of Medicine at Mount Sinai, New York, New York, United States; 3Nepean Hospital, Kingswood, New South Wales, Australia; 4Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia; 5St. Vincents Hospital Melbourne, Fitzroy, Victoria, Australia; 6Royal Melbourne Hospital, Parkville, Victoria, Australia; 7Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia; 8AbbVie Inc., North Chicago, Illinois, United States; 9University of Miami, Miami, Florida, United States; 10University of Chicago, Chicago, Illinois, United States; 11Johns Hopkins University, Lutheville, Maryland, United States; 12Royal Adelaide Hospital, Adelaide, South Australia, Australia; 13Texas Liver Institute, San Antonio, Texas, United States

0313171

0313172

0313173

0313174

0313175

0313176

0313177

0313178

0313179

03131710

03131711